Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

Starting a career in medical communications – experiences from the Nucleus Academy (part 2)

Two more graduates of the Nucleus Academy training programme share their experiences of the Academy and their medical communications careers to date.

Nucleus Global

- PMLiVE

GSK supports CEO Emma Walmsley following Elliott’s demands for leadership overhaul

GSK’s board said that it ‘strongly believes’ Walmsley is the ‘right leader’ for the new biopharma business

- PMLiVE

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data

- PMLiVE

UK Supreme Court rules in favour of Servier in NHS patent lawsuit

The NHS alleged that the French pharma company tried to block sales of generics versions of its drug Coversyl

- PMLiVE

Q&A: Claire Gillis

PME interviews VMLY&Rx's CEO

- PMLiVE

Mark Caulfield departs from Genomics England to take on CEO role at Barts Life Sciences

Caulfield served as chief scientist at Genomics England, working on the 100,000 Genomes Project

- PMLiVE

GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

The focus of the deal is two clinical-stage monoclonal antibodies in development for a number of neurodegenerative diseases

- PMLiVE

The Spirit of Lucid Group

Since 2017, Lucid Group’s charity working group, LUCID SPIRIT, has been actively involved in helping to raise awareness and funds for its charity partners. At launch, Lucid Spirit partnered with the...

Lucid Group Communications Limited

- PMLiVE

Nestlé and Seres announce new partnership for C.diff microbiome therapeutic

The companies will jointly commercialise Seres’ investigational oral microbiome therapeutic in the US and Canada

- PMLiVE

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

By George Forsyth

- PMLiVE

J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant

Vaccine produces durable immune responses lasting up to eight months

- PMLiVE

COVID-19 booster dose programme planned for September launch in Britain

The programme will be conducted in two stages for a range of priority groups

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links